Abstract
Lateral flow immunoassays (LFIAs) are paper-based diagnostic devices developed for analyte detection within a few minutes. However, one of the major challenges in advancing LFIA technology is the implementation of effective multiplexing strategies. At present, the simultaneous identification of multiple targets relies on the spatial separation of test lines or the use of different labels for readout, resulting in increasingly complex assay architectures.,In this work, we propose the integration of LFIA technology with Laser-Induced Breakdown Spectroscopy (LIBS). This technique enables rapid, multi-elemental analysis of the sample without any pretreatment, offering a novel readout strategy for multiplexed LFIA assays.,The feasibility of coupling LIBS with LFIA technology was explored by employing distinct metallic nanoparticles (NPs) as labels, each conjugated with a different antibody for a multiplex detection in a single test. By measuring the LIBS signal emitted by NPs captured on the test line, it should be possible to quantify the analytes to which they are bound.,As a proof of concept, gold, silver and platinum nanoparticles were functionalized with antibodies targeting the tetraspanin proteins CD9, CD81, and CD63, which are recognized biomarkers of Extracellular Vesicles (EVs). The three tetraspanins were simultaneously detected on neuronal EVs using a specifically designed LFIA platform in which antibodies against L1CAM, a selective marker of neuronal EVs, were immobilized on the test line to enable EV capture. Multiplexed detection was then achieved by applying a single laser pulse onto the test line and monitoring the characteristic emission lines of the three metallic labels.

This publication has 22 references indexed in Scilit: